Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study-Reference-Cited by-同舟云学术

Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study

Published:2020-09 Issue: Volume:89 Page:55-60.e6
ISSN:0301-472X
Container-title:Experimental Hematology
language:en
Short-container-title:Experimental Hematology

Author:

Saberi Hosnijeh Fatemeh,van der Straten Lina,Kater Arnon P.,van Oers Marinus H.J.,Posthuma Ward F.M.,Chamuleau Martine E.D.,Bellido Mar,Doorduijn Jeanette K.^ORCID,van Gelder Michel,Hoogendoorn Mels^ORCID,de Boer Fransien,te Raa G. Doreen,Kerst J. Martijn,Marijt Erik W.A.,Raymakers Reinier A.P.,Koene Harry R.,Schaafsma Martijn R.,Dobber Johan A.,Tonino Sanne H.,Kersting Sabina S.,Langerak Anton W.,Levin Mark-David

Funder

Dutch Cancer Society

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Genetics,Hematology,Molecular Biology

Reference15 articles.

1. The role of prognostic factors in assessing ‘high-risk’ subgroups of patients with chronic lymphocytic leukemia;Kay;Leukemia,2007

2. Lag times between lymphoproliferative disorder and clinical diagnosis of chronic lymphocytic leukemia: a prospective analysis using plasma soluble CD23;Kaaks;Cancer Epidemiol Biomarkers Prev,2015

3. Soluble B‐cell activation marker of sCD27 and sCD30 and future risk of B‐cell lymphomas: a nested case–control study and meta‐analyses;Hosnijeh;Int J Cancer,2016

4. Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies;Epstein;Haematologica,2018

5. Markers of immune activation and inflammation, and non-Hodgkin lymphoma: a meta-analysis of prospective studies;Makgoeng;JNCI Cancer Spectr,2019

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Study of LY9 as a potential biomarker for prognosis and prediction of immunotherapy efficacy in lung adenocarcinoma;PeerJ;2024-08-23

2. SLAM Family Receptors in B Cell Chronic Lymphoproliferative Disorders;International Journal of Molecular Sciences;2024-04-04

3. Quantitative proteomics characterization of cancer biomarkers and treatment;Molecular Therapy - Oncolytics;2021-06

4. NFAT5 Regulated by STUB1, Facilitates Malignant Cell Survival and p38 MAPK Activation by Upregulating AQP5 in Chronic Lymphocytic Leukemia;Biochemical Genetics;2021-02-05